00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
23:30 , Mar 6, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Ascendis, Sarepta

Ascendis and Sarepta each priced follow-ons, raising $500 million and $375 million, respectively, after the bell Tuesday. Invitae and CymaBay also priced follow-ons. Ascendis Pharma A/S (NASDAQ:ASND) raised $500 million through the sale of 4.2...
21:05 , Mar 4, 2019 |  BC Extra  |  Clinical News

Ascendis jumps on Phase III readout for once-weekly growth hormone

Ascendis gained $51.29 (74%) to $120.60 on Monday after reporting that its TransCon Growth Hormone met the primary endpoint in the Phase III heiGHt trial to treat pediatric growth hormone deficiency. The company plans to...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
20:25 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Ascendis raises $225M in bumped-up follow-on

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) raised $225 million on Feb. 22 through the sale of 3.9 million ADSs at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse, Wells...
20:03 , Feb 22, 2018 |  BC Extra  |  Financial News

Ascendis, Aimmune price upsized follow-ons

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) and allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised a total of $401 million late Wednesday in bumped-up follow-ons. Ascendis raised $225 million through the sale of 3.9 million ADSs...